[{"orgOrder":0,"company":"GSK","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Divestment","leadProduct":"Cefuroxime Axetil","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GSK","amount2":0.5,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.5,"dosageForm":"Tablet","sponsorNew":"GSK \/ Sandoz","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Sandoz"},{"orgOrder":0,"company":"GSK","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Cefuroxime Axetil","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Sandoz","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Sandoz"}]

Find Clinical Drug Pipeline Developments & Deals for Cefuroxime Axetil

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Through this transaction, Sandoz has acquired rights to three established brands (Zinnat, Zinacef and Fortum) in more than 100 markets, further reinforcing its leading global position in antibiotics.

                          Brand Name : Zinnat

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 11, 2021

                          Lead Product(s) : Cefuroxime Axetil

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Sandoz B2B

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          02

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Cephalosporin manufacturing will transfer from GSK sites to Sandoz following a four-year manufacturing and supply agreement (MSA) and subsequent transfer of manufacturing operations.

                          Brand Name : Zinnat

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          February 11, 2021

                          Lead Product(s) : Cefuroxime Axetil

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Sandoz B2B

                          Deal Size : $500.0 million

                          Deal Type : Divestment

                          blank